Harvard Bioscience, Inc., HBIO President Announces Completion of Stock Transactions under 10b5-1 Plan
HBIO President Announces Completion of Stock Transactions under 10b5-1 Plan
Wednesday November 1, 10:44 am ET
HOLLISTON, Mass Harvard Bioscience, Inc., (Nasdaq: HBIO - News) today announced that its president, David Green, has completed the stock transactions under a stock-trading plan in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 which was adopted on March 14, 2006.
The plan was adopted during an authorized trading period at a time when Mr. Green was not in possession of material, non-public information.
About Harvard Bioscience
Harvard Bioscience (HBIO) is a global developer, manufacturer, and marketer of a broad range of specialized products, primarily scientific instruments and apparatus, used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. HBIO sells its products to thousands of researchers in over 100 countries through its 1,100 page catalog (and various other specialty catalogs), its website and through its distributors, including GE Healthcare, Fisher Scientific and VWR. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Germany, and Austria with additional facilities in France and Canada.
Wednesday November 1, 10:44 am ET
HOLLISTON, Mass Harvard Bioscience, Inc., (Nasdaq: HBIO - News) today announced that its president, David Green, has completed the stock transactions under a stock-trading plan in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 which was adopted on March 14, 2006.
The plan was adopted during an authorized trading period at a time when Mr. Green was not in possession of material, non-public information.
About Harvard Bioscience
Harvard Bioscience (HBIO) is a global developer, manufacturer, and marketer of a broad range of specialized products, primarily scientific instruments and apparatus, used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. HBIO sells its products to thousands of researchers in over 100 countries through its 1,100 page catalog (and various other specialty catalogs), its website and through its distributors, including GE Healthcare, Fisher Scientific and VWR. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Germany, and Austria with additional facilities in France and Canada.
posted by Bill Austin - Harvard Bioscience, Inc., HBIO President Announces Completion of Stock Transactions under 10b5-1 Plan
0 Comments:
Post a Comment
Links to this post:
Create a Link
<< Home